Zolpidem on CPAP Acclimatization in OSA

• Status: Not yet recruiting
• Trial end date: 2024-10-15
• Target enrollment: 0
• Participant gender: All

Summary

Obstructive sleep apnea (OSA) is a sleep disorder characterized by a cessation or significant decrease in airflow during sleep. CPAP is the preferred therapy and has high effectiveness at all levels of OSA severity. It acts as a pneumatic splint to maintain upper airway patency during sleep, preventing the soft tissues from collapsing. However, the patient's compliance continues to be an issue. One of the main contributors to CPAP therapy failure is difficulty falling asleep. To aid in the machine's adaptation, hypnotic medicine was administered.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Siriraj Hospital
• Treatments: Zolpidem

Criteria

Inclusion Criteria:

• OSA patients whose sleep test demonstrated apnea-hypopnea index (AHI) ≥ 15 /hour or AHI ≥ 5 /hour with comorbid disease including hypertension, cardiovascular disease, and stroke

• Age 18 to 75 years

• Indicated for CPAP therapy

• Naïve for the device usage

Exclusion Criteria:

• A history of zolpidem allergies

• Currently take hypnotic medications

• Denied permission to engage in the study and/or follow its protocol

• Individuals with liver diseases, including hepatitis from any cause, liver cirrhosis, and liver cancer